Although further research is required to maximize the translational success of STAT3-targeting therapies in the clinic, key opportunities include the use of STAT3 as a biomarker to predict drug response, as well as a therapeutic target to overcome drug resistance and enhance the efficacy of current NSCLC treatment modalities. Here, STAT3 is linked to non-small cell lung carcinoma.